Research published in the journal Nature Communications identifies a significant link between the hormone asprosin and the pathophysiology of anorexia nervosa. According to findings from researchers at the Baylor College of Medicine, individuals with the eating disorder exhibit abnormally high levels of this glucose-regulating hormone, which may contribute to the persistent appetite suppression and metabolic shifts characteristic of the condition.
The Role of Asprosin in Appetite Regulation
Asprosin is a protein hormone primarily secreted by white adipose tissue. Under typical physiological conditions, it travels to the liver to stimulate glucose release and acts on the hypothalamus to influence appetite. In their study, published in May 2024, the research team observed that while patients with anorexia nervosa typically have low body fat—which would usually result in lower asprosin levels—these individuals paradoxically show elevated concentrations in their blood.
The researchers suggest that these high levels of asprosin may create a "false" signal of satiety or energy abundance in the brain. By interacting with specific neurons in the hypothalamus, the excess hormone appears to suppress hunger signals, even in states of severe caloric deficit. This mechanism may help explain why patients with anorexia nervosa often struggle with a profound loss of appetite despite being in a state of starvation.
Insights from Human and Mouse Models
To verify these findings, the team conducted both clinical observations and laboratory experiments. They analyzed blood samples from patients diagnosed with anorexia nervosa and compared them to healthy control groups, consistently finding higher asprosin levels in the patient cohort.
In subsequent experiments using mouse models, the researchers administered asprosin to healthy mice. The animals exhibited a marked reduction in food intake and weight loss, mimicking the metabolic profile observed in human patients. Conversely, blocking the action of asprosin in mice helped restore their appetite and weight, providing a potential target for future therapeutic interventions.
Clinical Implications for Eating Disorder Treatment
Current treatments for anorexia nervosa primarily focus on nutritional rehabilitation and psychotherapy, as there are currently no FDA-approved pharmacological treatments specifically for the disorder. The identification of asprosin as a potential metabolic driver offers a new perspective on the biological components of the illness.
According to the study authors, targeting the asprosin pathway could eventually lead to medications designed to normalize appetite regulation in patients. However, the researchers emphasize that this work is in the early stages. While the hormone plays a clear role in the metabolic dysregulation observed in the study, it represents only one piece of the complex psychological and biological puzzle that constitutes anorexia nervosa. Further clinical trials are required to determine if modulating this hormone is safe and effective for human patients.
Understanding Anorexia Nervosa
Anorexia nervosa is a serious mental health condition characterized by restricted food intake, leading to significantly low body weight and an intense fear of gaining weight. The National Institute of Mental Health (NIMH) notes that the disorder has one of the highest mortality rates of any mental health condition, often due to medical complications from starvation or suicide.
By identifying specific hormonal markers, scientists hope to move away from viewing the disorder solely as a behavioral choice and toward a more comprehensive understanding of the metabolic and neurological factors that sustain it. This shift in focus is intended to reduce the stigma associated with the condition and improve long-term recovery outcomes for patients.
Related reading